

## DAFTAR PUSTAKA

1. Lee SL. Hiperthyroidism. [www.emedicine.medscape.com](http://www.emedicine.medscape.com). 2017:3.
2. Ramos Levi AM, Marazuela M. Pathogenesis of thyroid autoimmun disease : The role of cellular mechanisms. *Endocrinol nutr* 2016; 63(8):421—29.
3. Yuan Q, Zhao X, Liu X. Association between CD4<sup>+</sup> Treg cell and Graves' Disease : A meta analysis. *J endocrine diabetes obes* 2017; 5(1) : 1097—105 .
4. Fumarola A, DiFiore M, Dainelli G, Calvanese A, Medical treatment of hyperthyroidism : state of the art. *Exp Clin Endocrinol Diabetes* 2010;1:1—7.
5. Djokomoeljanto R. Kelenjar Tiroid, Hipotiroidisme dan Hipertiroidisme. Buku Ajar Penyakit Dalam jilid III . Edisi IV. Juni 2006; 1933—58
6. Agrawal NK, Prakash V, sharma M. Thyroid hormon excess : Graves' dis. *intech open science* 2012 ;1 : 159—180.
7. Al-Humaidi MA. Serum Cytokines Level in Graves' Disease. *Saudi Med J* 2000;21(7):639—44.
8. John M, Sundrarajan R, Gumadam S. Antithyroid Drugs in Pediatric Graves' Disease. *Indian Journal of endocrinology and metabolic* 2015;19(3):340—6.
9. De groot LJ . Graves' Disease and The Manifestations of Thyrotoxicosis, 2015; 1 : 1—77.
10. Sundaresh V, Brito J, Wang Z, Prokop L, Stan M, Murad M et al. Hyperthyroidism : A Systematic Review and Network Metaanalysis. [jcem.endojournals.org](http://jcem.endojournals.org). 2013;1:1—7.
11. Mullur R, Liu YY, Brent GA. Thyroid Hormone Regulation of Metabolism. *Physiol rev*. 2014; 94:355—82.
12. Jameson J, Mandel S, weetman P. Disorder of thyroid Glands. *Harrison principal of internal medicine* 19th edition, feb 2007;2: 2283—308.
13. Djokomoeljanto R. Fisiologi Kelenjar Tiroid Sintesis, Sekresi, Metabolisme dan Efek Hormon Tiroid serta Faal Tiroid pada Berbagai Kondisi, Buku Ajar Tiroidologi Klinik. 2007;1: 52—11.

14. Nayak B, Burman K, Thyrotoxicosis and Thyroid storm, *Endocrinol metab clin N am.* 2006; 35 : 663—86.
15. DeReuiter J. Thyroid Hormone Tutorial : The Thyroid and Thyroid Hormones. *Endocrine Pharmacotherapy Module : Thyroid section .* 2001: 1—16.
16. Bartalena L,Diagnosis and Management of Graves' Disease: a Global Overview. *Nat. Rev. Endocrinol.* 2013; 9 :724—34.
17. Hwang SM, Kim MS, Lee DYI. Predictive Factors for Early Response to MMI in Children and Adolescents with Graves' Disease : a Single Institute Study Between 1993 and 2013. *Annals Pediatric Endocriinology and Metabolism.* 2016; 21:70—74.
18. Abraham P, Acharya S. Current and Emerging Treatment Option for Graves' Hyperthyroidism. *Therapeutics and Clinical Risk Management* 2010;6: 29—40.
19. Ross D, Burch H, Cooper D, Greenlee M, Laurberg P, Maia L et al. American Thyroid Association Guidelines for diagnosis and management of Hyperthyroidism and other causes of Thyrotoxicosis. 2016 ; 1: 1—272.
20. Klatka M, Grywalska E, Patryka M, Charytanowicz M, Bochynska AK, Rolinski J. Th17 and Treg cells in adolescents with Graves' disease. Impact of Treatment with Methimazole on These Cell Subsets. *Autoimmunity*, 2014; 47(3): 201—11.
21. Pedro AB, Romaldini JH, Takei K, Changes of serum cytokines in hyperthyroid Graves' Disease patients at Diagnosis and during Methimazole Treatment, *Neuroimmunomodulation* 2011;18: 45—51.
22. Marina Y .Tesis : Peran Propiltiourasil sebagai Terapi Inisial terhadap Kadar T3,T4 dan TSH dan IL-4 pada penyakt Graves. 2011. 1—99.
23. Decroli E, Manaf A, Syahbuddin S, Immunologic and Hormonal Effects of Prophythiouracil Treatment Using Maintenance Dose in Graves' Disease Patients, *Acta Med Indones-Indones J Intern Med*, 2014;46(4): 314—19.
24. Coralles JJ, Lopez A, Ciudad J, Mories MT, Miralles JM, Orfao A. Methimazole therapy in Graves' Disease Influence the Abnormal Expression of CD69 ( early activation antigen ) on T cell. *Journal of Endocrinology* 1997; 155: 491—500.
25. Smith TJ, Hegedus L, Graves' Disease, *N Engl J Med* 2016;375:1552—65.
26. Yeung SC. Graves' Disease. [www.emedicine.medscape.com](http://www.emedicine.medscape.com). 2017: 3: 1—5.

27. Raveinal. Nurhajjah S, Elvira D, Maulidia S. Polimorfisme gen TNF  $\alpha$  G 238A dan IL 4 T 34 C serta Hubungan dengan Kadar IL 4 dan TNF  $\alpha$  Pasien Penyakit Graves. MKA. 2014;37(2): 1—6.
28. Elvira D, The Role of T-Regulatory Expression in Autoimmune Thyroid Disease and its Association with Thyroid Antibody, *Journal of Autoimmune Disorders*, 2016; 2(2):1—4.
29. Burch H, Cooper DS, Management of Graves' Disease A Review, *JAMA* December 15, 2015; 314(23): 2544—54.
30. Christian M. Girgis, Bernard L. Champion and Jack R. Wall. Current concepts in Graves' disease. *Ther Adv Endocrinol Metab* 2011; 2(3) ;135—144.
31. Iddah MA, Macharia BN. Autoimmune thyroid disorders. Hindawi publishing Corporation ISRN Endocrinology 2013;1:1—10.
32. Eckstein AK, Lax H, Losch C, Losch, Glowacka D, Plicht M, Mann K et al, Patients with Severe Graves' Ophthalmopathy have a Higher Risk of Relapsing Hyperthyroidism and Are Unlikely to Remain in Remission, *Clinical Endocrinology*. 2007;67(4): 607—12.
33. Khong JJ, Pathogenesis of Thyroid Eyes Disease Review and Update on Molekuler Mechanisme, *Br J Ophthalmol* 2016;100 : 142—50.
34. Djokomoeljanto R. Kelenjar Tiroid, Hipotiroidisme dan Hipertiroidisme. Buku Ajar Ilmu Penyakit Dalam Jilid III Edisi IV FKUI, 2006: 1955—65
35. Pradhan S, Sarma H, Bhadravaz B, Mattaprathi V. Comparative Study on the Binding Affinity of MMI and PTU to TPO as an Anti Thyroid Drug : An In Silico Approach. *J Mol Imag Dynamic*. 2017;7(1): 1—9.
36. Morsyed SA, Latif R, Davies TF. Delineating the Autoimmune Mechanisms in Graves' disease. *Immunol Res*. December 2012; 54(0): 191—203.
37. Ginsberg J, Diagnosis and Management of. Graves' Disease, *CMAJ*. 2003;168 (5): 575—85.
38. Susanto R, Penyakit Graves pada Anak, Buku Ajar Tiroidologi Klinik, Edisi 2007: 441—69.
39. Bratanata KG, Rengganis I, Immunologi Dasar Edisi 11, Badan penerbit Fakultas kedokteran Univ Indonesia, Jakarta 2014: 660—62

40. Mao C, Impairment of regulatory capacity of CD4+CD25+Regulatory T cell Mediated by Dendritic Cell Polarization and Hyperthyroidism in Graves' dis, *J immunol* 2017; 186 : 4734—43.
41. Salvi Mm, Girasole G, Pedrazzoni M, Passeri M, Giuliani N, Minelli R et al, Increased Serum Concentrations of Interleukin-6 (il-6) and Soluble il-6 Receptor in Patients with Graves' Disease. *Journal of Clinical Endocrinology and Metabolism*. 1996; 81(8): 2976—9.
42. Xia N, Zhou S, Liang Y, Xiao C, Shen H, Pan H et al, CD4 T cells and the Th1/Th2 Imbalance are Implicated in Pathogenesis of Graves' Optahlmopathy. *International Journal of Molecular Medicine* 2006; 17: 911—916.
43. Kusrini I, Komorowulan S, Nilai Diagnostik Indeks Wayne dan Indeks New Castle untuk Penapisan Kasus Hipertroid, *Buletin Penelitian Kesehatan RI*, 2010: 38—43.
44. Larsen PR, Davies TF, Hay ID, *The Thyroid Gland*, William Textbook of Endocrinology. 2011; 134—144.
45. Girgis CM, Champion BL, wall JR. Current Concepts in Graves' Disease. *Ther adv endocrine metabolic* 2011;2(3):134—144.
46. The Indonesian Clinical Practice Guidelines for Hyperthyroidism, *Journal of The Asean Federation of Endocrine Societies*, 2012; 27(1):1—5.
47. Klatka M, Kaszubowska L, Grywalska E, Wasiak M, Szewczyk L, Foerster J et al. Treatment of Graves' Disease with MMI in Children Alters in Proliferation of Treg Cells and CD3+ T lymphocytes, *Folia Histochem Cytobiol*. 2014;52(1): 69—77.
48. Mitsiades N, Poulaki V, Tseleni-Balafouta S et al. Fas Ligand Expression in Thyroid Follicular Cell from Patient with Patient with Thionamide Treated Graves' Disease. *Thyroid* 2000; 10 : 527—32.
49. Cooper DS. Antithyroid Drugs. *N Engl J Med* 2005;352: 905—17.
50. Manna D, Roy G, Mugesh G. Antithyroid Drugs and Their Analogues: Synthesis, Structure and Mechanism of Action. *Account of Chemical Research*, may , 2013;30(20): 1—10.
51. Roy G, Mugesh G. Bioinorganic Chemistry in Thyroid Gland : Effect of Antithyroid Drugs on Peroxidase Catalyzed Oxidation and Iodination Reactions. *Bioinorganic Chemistry and Applications*. 2006;2006:1—9.

52. Yamada T, komiya I, Miyahara Y, Komatsu M, Shima I, inazawa T, aizawa T. Effect of methimazole treatment for 2 years on circulating IL-4, IgE, TBII dan TSAb in patient with Hypertiroid Graves' Disease. *Endocrine Journal* 2006 ;53(6): 783—88.
53. He CT, Hsieh AT, pei D, hung YJ, wu LY, yang TC et al . Comparison of Single Daily Dose of MMI and PTU in The Treatment of Graves' Hyperthyroidism, *Clinical Endocrinology*. 2004; 60: 676—81.
54. John M, Sundrarajan R, Gomadam S. Anti Thyroid Drugs in Pediatric Graves' Disease. *Indian Journal of Endocrinology and Metabolism* 2015;19(3):340—6.
55. Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N. Comparison of Methimazole and Propylthiouracil in Patient with Hyperthyroidism caused by Graves' Disease , *J Clin Endocrinol Metab* , June 2007; 92(6): 2157—62.
56. Tagami T, Yambe Y, Tanaka T, Ogo A, Yoshizumi H, Kaise K et al. BBGD Study Group 2012 Short-term Effects of BetaAdrenergic Antagonists and Methimazole in New-Onset Thyrotoxicosis Caused by Graves' Disease. *Intern Med* 2012; 51:2285—90.
57. Pagana K, Pagana T. *Mosby's Manual of Diagnostic and Laboratory Tests* Missouri: Elsevier. 2002.
58. Demers LM, Spencer C. The thyroid: Pathophysiology and Thyroid Function Testing. *Tietz Textbook of Clinical Chemistry and Molecular Diagnostics*. St Louis:Elsevier Saunders, edisi 4, 2006; 2053—95.
59. Lombardi A, Menconi F, Greenberg D, Concepcion E, Leo M, Rocchi R et al. Dissecting the Genetic Susceptibility to Graves' Disease in a Cohort of Patient of Italian Origin. *Frontiers in Endocrinology*. 2016;7(21); 1—7.
60. Planck T, Shahida B, Malm J, Manjer J. Vitamin D in Graves Disease: Levels, Correlation with Laboratory and Clinical Parameters and Genetics. *Eur Thyroid J*.2018; 7(1): 27—33.
61. Cui Z, Wang Z, Liu X, Cai Y, Xu X, Yang T. Establishment of clinical diagnosis model of Graves' and Hashimoto's thyroiditis. *Journal of translational medicine*.2019;17(11):1—6 .
62. Sarfo-kantanka O, Sarfo F, Ansah E, Kyel I. Graves disease in central Ghana : Clinical Characteristic and associated factors. *Clinical medical insight: endocrinology and Diabetes*. 2018;11:1—7.

63. Priatna, Yuslianti E, Nova S, Hidayat. Effect of Radioiodine (I-131) to TSH, T3 and FT4 Hormone Levels in Hyperthyroidism High Uptake Patient. *Trends in Meds Res.* 2017;12(1):14—19.
64. Gebreyohannes E, Ayele E, Tesfaye S, Seid M. Normalization of thyroid function test among thyrotoxicosis patients attending a University Hospital in North West Ethiopia. *Thyroid Res.* 2019; 12(3):1—8.
65. Juwita DA, suhatri, Hesti R, evaluasi penggunaan obat antitiroid pada pasien hipertiroid di RSUP Dr M Djamil Padang, Indonesia, *Jurnal sains farmasi dan klinis.* 2018; 5(1): 49—54.
66. Liu J, Fu J, Xu Y, Wang G. Antithyroid drug therapy for Graves' disease and implications for recurrence. *International journal of Endocrinology.* 2017; 1 :1—8 .
67. Bremner A, Feddema P, Leedman P, Brown S, Beilby J, Lim E et al. Age Related Change in Thyroid Function : A Longitudinal Study of a Community Bases Cohort. *J Clin Endocrinol Metab.* 2012; 97(5): 1554—62.
68. Hadlow NC, Rothacker KM, Wardrop R, Brown SJ, Lim EM, Walsh JP. The Relationship between TSH and Free T4 in a Large Population is Complex and Non Linear and differs by Age and Sex. *J Clin Endocrinol Metab:* 2103; 98(7): 2936—43.
69. Shi GM, Xu Q, Zhu CY, Yang YL. Influence of propylthiouracil and Methimazole pre treatment on outcome of I-131 Therapy in Hyperthyroid patient with Graves' Disease. *The Journal of International Medical Research* 2009;37(2):576—82.
70. Hendromartono. The Treatment Modality of Graves' Disease. In Djokomoeljanto, Darmono , Suhartono T, Pemayun T, Nugroho H. *Naskah Lengkap Temu Ilmiah dan Simposium Nasional IV Penyakit Kelenjar Tiroid.* Semarang: Badan Penerbit Universitas Diponegoro Semarang; 2005.
71. Koenig RJ. Regulation of type I iodothyronin deiodinase in health and disease. *Thyroid* 2005;15(8): 835—40 .
72. Laurberg P. Remission of Graves' disease during anti-thyroid drug therapy, time to reconsider the mechanism? *Eur J Endocrinol.* 2006; 155(6): 783—6.
73. Kocjan T, Wraber B, Kocijancic A, Hojker S. Methimazole upregulates T cell derived cytokines without improving the existing Th1/Th2 imbalance in Graves' Disease . *J endocrine invest.* 2004;27(4):302—7.

74. Montani V, Shong M, Tanigushi SI. Regulation of major histocompatibility class II gene expression in FRTL-5 Thyrocytes: opposites effects of interferon and methimazole. *Endocrinology* . 1998;139 : 290—302.
75. Okamura, K., Ikenoue, H., Shiroozu, A., Sato, K., Yoshinari, M. & Fujishima, M. (1987) Re-evaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves' hyperthyroidism. *Journal of Clinical Endocrinology and Metabolism*.1987; 65(4): 719—23.
76. Shiroozu, A., Okamura, K., Ikenoue, H., Sato, K., Nakashima, T.Yoshinari, M., Fujishima, M. & Yoshizumi, T. (1986) Treatment of hyperthyroidism with a small single daily dose of methimazole. *Journal of Clinical Endocrinology and Metabolism*. 1986; 63(1): 125—28.
77. Jansson, R., Dahlberg, P.A., Johansson, H. & Lindstrom, B. Intrathyroidal concentrations of methimazole in patients with Graves' disease. *Journal of Clinical Endocrinology and Metabolism*. 1983; 57(1): 129—32.
78. Choo YK, Yoo WS, Kim DW, Chung HK. Hypothyroidism during antithyroid Drug treatment with Methimazole as a Favorable Prognostic Indicator in Patient with Graves' Disease. *Thyroid*; 2010; 20(9): 949—54.
79. Homsanit M, Sriussadaporn S, Vannasaeng S, Peerapatdit T, Nitiyanant W, Vichayanrat A. Afficacy of single daily dosage of methimazole vs prophythiouracil in the induction of euthyroidism. *clinical endocrinology*. 2001;54 : 385—90.

